# Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

> **NCT01177683** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sherif Farag, MB, BS** · enrollment: 32 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Doxorubicin
- **DRUG:** Bortezomib
- **DRUG:** Bendamustine
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT01177683
- **Lead sponsor:** Sherif Farag, MB, BS
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Lack of accrual
- **Last updated:** 2023-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177683, "Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01177683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*